XF-73

XF-73
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C44H50N6O2.2ClH/c1-49(2,3)25-7-27-51-37-17-9-31(10-18-37)43-39-21-13-33(45-39)29-35-15-23-41(47-35)44(42-24-16-36(48-42)30-34-14-22-40(43)46-34)32-11-19-38(20-12-32)52-28-8-26-50(4,5)6;;/h9-24,29-30,45-46H,7-8,25-28H2,1-6H3;2*1H/q+2;;/p-2/b33-29-,34-30-,35-29-,36-30-,43-39-,43-40-,44-41-,44-42-;;
    Key: BXHQXSXRVAELBC-XRFOENPRSA-L
  • InChI=1/C44H50N6O2.2ClH/c1-49(2,3)25-7-27-51-37-17-9-31(10-18-37)43-39-21-13-33(45-39)29-35-15-23-41(47-35)44(42-24-16-36(48-42)30-34-14-22-40(43)46-34)32-11-19-38(20-12-32)52-28-8-26-50(4,5)6;;/h9-24,29-30,45-46H,7-8,25-28H2,1-6H3;2*1H/q+2;;/p-2/b33-29-,34-30-,35-29-,36-30-,43-39-,43-40-,44-41-,44-42-;;
    Key: BXHQXSXRVAELBC-NDLTUMITBE
  • C[N+](C)(C)CCCOC(C=C1)=CC=C1/C(C2=CC=C(/C=C3C=CC(/C(C4=CC=C(OCCC[N+](C)(C)C)C=C4)=C(N/5)/C=CC5=C\6)=N/3)N2)=C7N=C6C=C/7.[Cl-].[Cl-]
Properties
C44H50Cl2N6O2
Molar mass 765.82 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

XF-73 (Exeporfinium chloride) is an experimental drug candidate. It is an anti-microbial that works via weakening bacteria cell walls.[1] It is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridium difficile. It is being developed by Destiny Pharma Ltd.[2][3][4]

Structurally, it is a dicationic porphyrin.[5]

It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.[1][6]

In 2014, a phase 1 clinical trial for nasal administration was run.[7]

As of June 2022, another phase 1 clinical trial (for nasal administration) completed recruiting in 2016 but no results have been posted.[8]

References
  1. Neka Sehgal (20 September 2010). "Promising new drug XF-73 kills superbugs within 5 minutes". Archived from the original on 21 July 2011.
  2. "XF-73". Destiny Pharma. 29 July 2016. (Shows molecular structure.)
  3. Miller, K.; Ooi, N.; Hobbs, J. K.; Rhys-Williams, W.; Love, W. G.; Hayter, I.; Katila, M.; Chopra, I. (19 April 2008). "XF-73, a novel anti-staphylococcal antimicrobial with very rapid bactericidal activity". European Society of Clinical Microbiology and Infectious Diseases. {{cite journal}}: Cite journal requires |journal= (help)
  4. Mary Dejevsky (18 May 2008). "Scientists 'on brink of cure' for superbug". The Independent. Archived from the original on 7 May 2022.
  5. "XF series". Destiny Pharma. 29 July 2016.
  6. Tom Chivers (18 May 2008). "MRSA: UK scientists 'close to a treatment". The Daily Telegraph. Archived from the original on 21 April 2013.
  7. Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
  8. Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.